| 產品編號 | bsm-30156A |
| 英文名稱 | mouse CD19 Rat mAb |
| 中文名稱 | 小鼠CD19單克隆抗體 |
| 別 名 | Antibody deficiency due to defect in CD19, included; AW495831; B lymphocyte antigen CD19; B lymphocyte surface antigen B4; B4; CD 19; CD19 antigen; CD19 molecule; Cd19 protein; Differentiation Antigen CD19; Leu 12; Leu12; Lymphocyte Surface Antigen; MGC109570; MGC12802; T-cell surface antigen Leu-12; CD19_MOUSE. |
| 抗體來源 | Rat |
| 克隆類型 | Monoclonal |
| 克 隆 號 | 5C7 |
| 交叉反應 | Mouse |
| 產品應用 | Flow-Cyt=1:50-100
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 59 kDa |
| 檢測分子量 | 90 |
| 性 狀 | Liquid |
| 亞 型 | Rat IgG2a,k |
| 純化方法 | affinity purified by Protein G |
| 緩 沖 液 | 0.01M TBS (pH7.4). |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020] |
| 產品圖片 |
scatter diagram showing mouse spleen cells stained with bsm-30156A. The cells were incubated with the antibody (bsm-30156A,1 μg/Test) for 30 min at 22°C.The secondary antibody used for 40 min at room temperature. Acquisition of >20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
